Peter Parker is currently Managing General Partner of Mission BioCapital (Mission). He is a co-founder of BioInnovation Capital, an early stage life sciences venture capital firm and the immediate predecessor of Mission. He was a Venture Partner at Mission Bay Capital (MBC) in San Francisco, which also now created Mission. Both funds invest in start-up companies based in our network of shared laboratories across the US. For the past three decades, Peter has focused on early stage company formation, funding, and growth. He has been an equity investor and Board member in over 30 companies. Peter was a General Partner at Ampersand Ventures from 1988-2006 and co-led the establishment of their life sciences franchise. The sectors where he has invested extensively include tools, devices, diagnostics, therapeutics and drug delivery. For the past 10 years, Peter has played a major role in the greater Boston/Cambridge start-up ecosystem. At MassChallenge, he was the healthcare/life sciences ‘Champion’ for five years; the original curriculum manager of that vertical for the Boston accelerator. He is also one of three co-founders of LabCentral, Inc, a not-for-profit shared facility for companies who need biolab space in Kendall Sq. In 2014, Peter was appointed to the Board of the Massachusetts Life Sciences Center by Governor Deval Patrick.
As an early stage investor, Peter provided the first institutional capital in over two dozen companies including: ACLARA Biosciences (NSDQ: ACLA), Alexis (Chairman, sold to Q-biogene), CoPharma (Chairman, sold to Lonza), Cyclis Pharmaceuticals (Chairman, sold to Arqule), Huntington Laboratories (Chairman, sold to EcoLab), Nanodyne (Chairman, sold to UmiCore), NOVEX (Chairman, sold to Invitrogen), Panacos Pharmaceuticals (Chairman, public/reverse merger and PIPE with Vitex), Pentose Pharmaceuticals (sold to Vitex), Protein Ingredient Technologies (Chairman, sold to Associated British Foods). Beginning in 2006, Peter became President and CEO of Cequent Pharmaceuticals, Inc. (based on the research of Johannes Fruehauf) which was sold to Marina Biotech (NSDQ: MRNA) in July 2010. He then invested as an angel in 10 local start-ups including Boston Heart Diagnostics (Chairman, sold to Eurofins) and AbVitro (sold to Juno).
For BioInnovation Capital, Peter joined the Boards of Vedere, Alessa, Photoswitch BioSciences, and Mitokinin. Prior to Ampersand, Peter was head of worldwide R&D for AMAX Inc, a Fortune 50 industrial company. He oversaw all research activities at AMAX’s three labs (in NJ, CO, and MI) which employed 750 scientists.Peter holds a B.S. and an M.S. degree in Chemical Engineering from Columbia University
Steve Tregay, PhD joined Mission BioCapital full time as Managing General Partner in 2019 after acting as the Chairman of the Advisory Board for the first BioInnovation Capital fund. He oversees fund activities in Cambridge and focuses on opportunities in therapeutics and platform technologies. In addition to new investment activities, Steve leverages his extensive transaction experience to work closely with portfolio companies to drive value creation. Steve is also currently the Chairman of the Board at LabCentral and has been involved since its creation in 2012.
Previously, Steve was Founder, President, and CEO of FORMA Therapeutics, a company building a robust pipeline of transformative cancer therapeutics directed in areas such as tumor metabolism, epigenetics, protein-protein interactions, and protein homeostasis. Steve led the company for 10 years, during which FORMA secured over $875M in non-dilutive funding with only $44M in venture capital investment. To date, the company has advanced seven clinical candidates across oncology, sickle cell, and liver diseases. In 2019, Steve transitioned CEO leadership to Frank Lee from Genentech to prepare the company for NDA submission and commercialization in 2020. In addition, Steve is also co-founder and Chairman of the Board of Compass Therapeutics, a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multi-specific antibody therapeutics.
Prior to FORMA, Steve was a managing director for the Novartis Venture Fund. He led the fund’s investments in and served on the board of directors of FORMA Therapeutics, Adenosine Therapeutics (sold to Clinical Data: FRX) and Cequent Pharmaceuticals (sold to Marina Biotech: MRNA), where he first began working with the BioInnovation team. Prior to joining the venture fund, Steve was the Executive Director and Head of Strategic Alliances – Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development and research at Array BioPharma.
Steve received his doctoral and master’s degrees in organic chemistry from Harvard University and a bachelor’s degree from Davidson College.